64 related articles for article (PubMed ID: 26819954)
1. Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer.
Boylan KLM; Petersen A; Starr TK; Pu X; Geller MA; Bast RC; Lu KH; Cavallaro U; Connolly DC; Elias KM; Cramer DW; Pejovic T; Skubitz APN
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804849
[TBL] [Abstract][Full Text] [Related]
2. Bayesian and deep-learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers.
Abrego L; Zaikin A; Marino IP; Krivonosov MI; Jacobs I; Menon U; Gentry-Maharaj A; Blyuss O
Cancer Med; 2024 Apr; 13(7):e7163. PubMed ID: 38597129
[TBL] [Abstract][Full Text] [Related]
3. Tasks and Experiences of the Prospective, Longitudinal, Multicenter MoMar (Molecular Markers) Study for the Early Detection of Mesothelioma in Individuals Formerly Exposed to Asbestos Using Liquid Biopsies.
Weber DG; Casjens S; Wichert K; Lehnert M; Taeger D; Rihs HP; Brüning T; Johnen G; The MoMar Study Group
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136442
[TBL] [Abstract][Full Text] [Related]
4. Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
[TBL] [Abstract][Full Text] [Related]
5. Exploring solid-phase proximity ligation assay for survivin detection in urine.
Gleichenhagen J; Arndt C; Casjens S; Töpfer C; Gerullis H; Raiko I; Taeger D; Ecke T; Brüning T; Johnen G
PLoS One; 2022; 17(6):e0270535. PubMed ID: 35767525
[TBL] [Abstract][Full Text] [Related]
6. New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers.
Holcakova J; Bartosik M; Anton M; Minar L; Hausnerova J; Bednarikova M; Weinberger V; Hrstka R
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944963
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the treatment response in ovarian cancer: a ctDNA approach.
Sharbatoghli M; Vafaei S; Aboulkheyr Es H; Asadi-Lari M; Totonchi M; Madjd Z
J Ovarian Res; 2020 Oct; 13(1):124. PubMed ID: 33076944
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers and Strategies for Early Detection of Ovarian Cancer.
Bast RC; Lu Z; Han CY; Lu KH; Anderson KS; Drescher CW; Skates SJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2504-2512. PubMed ID: 33051337
[TBL] [Abstract][Full Text] [Related]
9. Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
Gentry-Maharaj A; Blyuss O; Ryan A; Burnell M; Karpinskyj C; Gunu R; Kalsi JK; Dawnay A; Marino IP; Manchanda R; Lu K; Yang WL; Timms JF; Parmar M; Skates SJ; Bast RC; Jacobs IJ; Zaikin A; Menon U
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708856
[TBL] [Abstract][Full Text] [Related]
10. Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet?
Grayson K; Gregory E; Khan G; Guinn BA
Biomark Cancer; 2019; 11():1179299X19830977. PubMed ID: 30833816
[TBL] [Abstract][Full Text] [Related]
11. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.
Weber DG; Brik A; Casjens S; Burek K; Lehnert M; Pesch B; Taeger D; Brüning T; Johnen G;
BMC Res Notes; 2019 Feb; 12(1):77. PubMed ID: 30744695
[TBL] [Abstract][Full Text] [Related]
12. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
[TBL] [Abstract][Full Text] [Related]
13. A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer.
Vázquez MA; Mariño IP; Blyuss O; Ryan A; Gentry-Maharaj A; Kalsi J; Manchanda R; Jacobs I; Menon U; Zaikin A
Biomed Signal Process Control; 2018 Sep; 46():86-93. PubMed ID: 30245736
[TBL] [Abstract][Full Text] [Related]
14. Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.
Yeh CY; Adusumilli R; Kullolli M; Mallick P; John EM; Pitteri SJ
Biomark Res; 2017; 5():30. PubMed ID: 29075496
[TBL] [Abstract][Full Text] [Related]
15. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
[TBL] [Abstract][Full Text] [Related]
16. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
17. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.
Blyuss O; Gentry-Maharaj A; Fourkala EO; Ryan A; Zaikin A; Menon U; Jacobs I; Timms JF
Biomed Res Int; 2015; 2015():681416. PubMed ID: 26819954
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
